NCT02793128 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- This was a prospective, open-label, single-arm, pivotal phase study, designed to assess the efficacy, tolerability, and safety UGN-101 treatment administered to the Upper Urinary Tract (UUT). Upon signing of informed consent, the patients underwent a Screening Visit for eligibility evaluation. Eligible patients with confirmed low grade (LG) noninvasive Upper Tract Urothelial Carcinoma (UTUC) were treated with 6 once-weekly instillations of UGN-101. Tumor response was evaluated at the Primary Disease Evaluation (PDE) Visit, 5 weeks after the last treatment period instillation. Patients who demonstrated complete response (CR) could enter a maintenance period and receive up to 11 once-monthly instillations, per investigator modified treatment regimen.
- id
- FG000
- title
- UGN-101 Mitomycin for Pyelocalyceal Solution
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 4
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Comorbid conditions and noncompliance
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Patient elected nephroureterectomy
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 71
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 62
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 9
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- This was a prospective, open-label, single-arm, pivotal phase study, designed to assess the efficacy, tolerability, and safety UGN-101 treatment administered to the Upper Urinary Tract (UUT). Upon signing of informed consent, the patients underwent a Screening Visit for eligibility evaluation. Eligible patients with confirmed low grade (LG) noninvasive Upper Tract Urothelial Carcinoma (UTUC) were treated with 6 once-weekly instillations of UGN-101. Tumor response was evaluated at the Primary Disease Evaluation (PDE) Visit, 5 weeks after the last treatment period instillation. Patients who demonstrated complete response (CR) could enter a maintenance period and receive up to 11 once-monthly instillations, per investigator modified treatment regimen.
- id
- FG000
- title
- UGN-101 Mitomycin for Pyelocalyceal Solution
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 4
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Comorbid conditions and noncompliance
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Patient elected nephroureterectomy
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 71
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 62
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 9
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle